Retatrutide (10 mg vial)

Retatrutide (10 mg vial)

Primary use: Advanced weight loss and metabolic disease management.

Mechanism / class: Triple agonist — GLP-1 receptor + GIP receptor + glucagon receptor

Key effects:

• Significant appetite suppression (GLP-1 pathway)

• Enhanced insulin sensitivity and glucose regulation (GLP-1 + GIP)

• Increased energy expenditure and fat oxidation (glucagon pathway)

• Produces substantial total body weight reduction in clinical trials

Clinical distinction:
Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide adds glucagon receptor activation, which may increase metabolic rate and fat oxidation in addition to appetite suppression; currently investigational and not yet FDA-approved.

Retatrutide is supplied strictly for research and development purposes only. Not for human or veterinary consumption.